Compass Pathways Q2 2026 earnings: Warrant revaluation drives wider net loss

Compass Pathways (NASDAQ: CMPS) reported a Q2 2026 net loss of $253.8 million, or $1.88 per basic and diluted share, compared with $38.4 million, or $0.41 per share, a year earlier. Most of the widening came from a $205.6 million non-cash warrant fair-value loss, although operating expenses also increased as the company expanded commercial-readiness activities. Cash and cash equivalents reached $433.3 million at quarter-end, while the rolling COMP360 regulatory submission remained on track for completion in Q4 2026.

Core financial results

Compass Pathways’ operating loss widened by approximately 22% to $52.4 million. General and administrative expense rose sharply because of commercial-preparation spending, more than offsetting lower research and development expense as the COMP360 Phase 3 program moved toward completion.

The much larger increase in the reported net loss primarily reflected warrant accounting rather than operating costs. All figures below cover the three months ended June 30.

Lower R&D spending reflected reduced clinical-trial costs as the Phase 3 TRD program progressed toward completion, along with lower discovery-program costs following earlier program terminations. Higher consulting, contractor and facilities expenses partly offset those savings.

COMP360 clinical and regulatory progress

Compass reported positive results from the COMP005 and COMP006 Phase 3 trials of COMP360 in treatment-resistant depression. Participants represented a chronic population, with current depressive episodes lasting more than three years on average and more than six lifetime depressive episodes on average.

Among participants achieving a clinically meaningful reduction in MADRS scores of at least 25%, an effect was observed beginning the day after administration. At week six, 39% of COMP006 participants and 25% of COMP005 participants achieved a reduction greater than 25%, with benefit maintained on average through at least week 26. The company also said most treatment-emergent adverse events were transient and occurred mainly on the dosing day, while serious adverse events were low across both trials.

The FDA granted a rolling NDA submission and review request in April. Initial review is underway, some modules have already been submitted, and Compass expects to complete the remaining modules in Q4 2026. A National Priority Voucher could shorten the review period, but the company cautioned that the program may not necessarily produce a faster review or approval.

Compass is also conducting a late-stage COMP360 trial in post-traumatic stress disorder. No new financial contribution from that program was reported for the quarter.

Warrant revaluation magnified the loss beyond operating performance

The difference between the $52.4 million operating loss and the $253.8 million net loss is central to interpreting the quarter. Compass recorded $201.1 million of total net other expense, dominated by the $205.6 million warrant fair-value adjustment.

This adjustment was non-cash and can vary substantially because the warrant liability is remeasured as the company’s share price changes. It therefore did not represent an equivalent amount of clinical or commercial spending during the quarter. Nevertheless, the underlying cost base also increased: an approximately $10.6 million rise in G&A expense exceeded the roughly $1.2 million reduction in R&D expense.

Cash runway and balance sheet

Cash and cash equivalents increased to $433.3 million as of June 30, 2026, from $149.6 million at the end of 2025. Debt rose to $50.7 million from $31.6 million over the same period, leaving approximately $382.6 million of cash in excess of debt.

Warrant liabilities increased to $337.5 million from $203.7 million. This liability helps explain the quarterly fair-value expense, but it should be distinguished from debt and current operating cash expenditures.

Guidance and upcoming milestones

Management expects the current cash position to fund operating expenses and capital expenditures into 2028. That timeline extends beyond the company’s targeted commercial launch, though both approval and launch timing remain conditional.

Compass said its launch preparations include provider training, site readiness, reimbursement assistance and patient support. The company believes COMP360 can be delivered through existing infrastructure that includes more than 8,000 U.S. centers offering multi-hour treatments.

Risks investors need to watch

• FDA approval remains uncertain: Positive Phase 3 findings support the NDA, but the complete data and regulatory review must still establish acceptable efficacy and safety.
• An accelerated review is not guaranteed: Rolling review and the National Priority Voucher may shorten the process, but neither ensures faster approval.
• Rescheduling could affect launch timing: Even after potential FDA approval, DEA and state rescheduling decisions are required before COMP360 can be commercialized in the United States.
• Commercial adoption and reimbursement are unproven: Site preparation, payer coverage, provider acceptance and patient access will determine whether clinical progress translates into product uptake.
• Commercial-readiness costs are already increasing: G&A expense rose approximately 84% year over year, creating additional operating pressure before COMP360 generates commercial sales.

Summary

Compass Pathways’ Q2 2026 headline loss was primarily enlarged by a non-cash warrant revaluation, but underlying operating expenses also rose as the company prepared for a potential COMP360 launch. Positive Phase 3 results, the rolling NDA and $433.3 million cash balance support the transition toward regulatory review, while FDA approval, controlled-substance rescheduling, reimbursement and the higher commercial cost base remain the main issues to monitor.